Category: Cardiac Rhythm Management
Sales of its cardiac rhythm management devices help boost Boston Scientific above expectations for the 3rd quarter.
Boston Scientific says it won CE Mark approval in the European Union for its Accolade line of MRI-safe pacemakers.
The U.S. Supreme Court declines to revisit a lower court ruling against Mirowski Family Ventures in its ongoing patent litigation against Medtronic.
Medtronic says the FDA approved its CapSureFix Novus MRI SureScan 5076 pacemaker lead for full-body MRI scans in patients with its Advisa MRI or Revo MRI SureScan pacemakers.
Medtronic (NYSE:MDT) said today that the FDA approved its CapSureFix Novus MRI SureScan 5076 lead in MRI scans for patients with a Medtronic dual-chamber MR-conditional pacemaker.
Acutus Medical secured $26.2 million in new funding for its cardiac mapping technology.
Acutus Medical said it secured $26.2 million in new funding for the cardiac mapping technology it's developing to image and map atrial fibrillation hotspots.
Despite Boston Scientific having yet to debut a pacemaker that nestles inside the heart itself, an analyst said the company may be best positioned to capitalize on sales of such devices.
Boston Scientific loses a $309 million judgment in its long-running patent war with Mirowski Family ventures over cardiac pacemaker technology.
UPDATED Sept. 25, 2014, with comment from Boston Scientific.